# Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients

> **NCT00186940** · — · COMPLETED · sponsor: **St. Jude Children's Research Hospital** · enrollment: 16 (actual)

## Conditions studied

- Leukemia
- Lymphoma
- Tumor Lysis Syndrome
- Hyperuricemia

## Interventions

- **DRUG:** Rasburicase

## Key facts

- **NCT ID:** NCT00186940
- **Lead sponsor:** St. Jude Children's Research Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2010-02
- **Final completion:** 2010-02
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2017-04-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00186940

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00186940, "Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00186940. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*